Research Brief: J&J to Buy Elan’s Aβ Immunotherapy Program
2 July 2009. Elan’s Alzheimer immunotherapy program (AIP) has gotten a booster. The company announced today that Johnson & Johnson has agreed to acquire all the assets of the program for an injection of $1 billion—the equivalent of ~18 percent of outstanding Elan ordinary shares. Through a new affiliate, Johnson & Johnson will continue the AIP in collaboration with Wyeth, and will also contribute $500 million for the development of bapineuzumab, a humanized monoclonal antibody against amyloidβ, the peptide found in senile plaques (see ARF related news story). Elan will own 49.9 percent of the new company according to a press release issued today.
Bapineuzumab is currently in Phase 3 clinical trials (see ARF related news story), and Elan has other immunotherapies for Alzheimer disease in the pipeline, including another monoclonal antibody AAB-001 and an Aβ vaccine (see ARF related news story). For more information on the new merger, see today’s New York Times.—Tom Fagan.
An up-to-date collection of all published genetic association studies.
The AlzRisk Epidemiology Database provides a publicly available collection of published studies on the impact of putative environmental risk factors and protective factors related to Alzheimer disease in longitudinal cohort studies.
With their new ADDF ACCESS resource,
the Alzheimer's Drug Discovery Foundation provides a network of contract research organizations
(CROs) that offer commercial services to help accelerate drug development.